SUBSCRIBE
SUBSCRIBE
News   Policy

Astellas Pharma Inc. Sees U.S. Delay on Transplant Drug Advagraf

March 14, 2008 | 
1 min read
TOKYO (Reuters) - Japan's Astellas Pharma Inc said on Friday that U.S. authorities have requested more information on its key kidney transplant drug Advagraf, meaning it will face further delays in receiving approval there.
Regulatory Asia
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
 · 
2 min read
 · 
Heather McKenzie
Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA, 3d illustration
FDA
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta
February 25, 2026
 · 
6 min read
 · 
Joshua R. Mansbach
screenshot of Marty Makary speaking on the Megyn Kelly Show
Vaccines
FDA’s Makary Backs mRNA Vaccines but Says Companies ‘Can Fund Their Own Research’
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac